BioCentury | Jan 8, 2015
Translation in Brief

Uptick for Lyme vaccine

Commercial interest in Lyme disease has all but ground to a halt since the withdrawal of the first vaccine, Lymerix, more than a decade ago, despite a tenfold increase in the U.S. incidence of the...
BioCentury | Jul 27, 1998
Company News

Cytokine other research news

...the potential for the agent to prevent toxicity from IL-2 and IL-12 in cancer treatment. Cytokine Networks Inc....
BioCentury | Jul 27, 1998
Company News

Cytokine other research news

...cells, the company said. Phase I testing of these cells as cancer therapy is ongoing. Cytokine Networks Inc....
BioCentury | Jul 27, 1998
Company News

Cytokine other research news

...the role of polyamine blockers in promoting the action of tumor necrosis factor against cancers. Cytokine Networks Inc....
BioCentury | Jun 8, 1998
Emerging Company Profile

Cytokine Networks Inc.

Cytokine Networks Inc. Seattle, Wash. Technology: Cytokine inhibitors, antivirals and vaccines to prevent disease Disease focus: Cancer, inflammatory diseases and HIV infection Clinical status: Phase I Founded: 1993 by the Picower Institute for Medical Research...
BioCentury | Jun 8, 1998
Emerging Company Profile

Cytokine Networks: Ready-made pipeline

...but not given a mandate to become an operating drug development company until December 1996, Cytokine Networks Inc....
BioCentury | Jun 1, 1998
Clinical News

CNI-1493 small molecule inhibitor of IL-2 toxicities: Cytokine Networks began U.S. Phase I testing

...CNI-1493 small molecule inhibitor of IL-2 toxicities Indication: Adjunct to IL-2 in cancer therapies Status: Cytokine Networks...
BioCentury | Apr 13, 1998
Clinical News

Autologous fibrocyte antigen-presenting cells: Cytokine Networks began Phase I testing

...Seattle, Wash. Product: Autologous fibrocyte antigen-presenting cells Indication: Treat sarcoma, melanoma and other cancers Status: Cytokine Networks...
BioCentury | Sep 15, 1997
Company News

Cytokine, Idec deal

...IDPH exclusively licensed therapeutic and diagnostic applications of Cytokine Networks' anti-macrophage inhibitory factor ( MIF ) antibody...
...MIF ) antibody technology. IDPH will make a $3 million preferred equity investment in Cytokine Networks...
...is designed to inhibit MIF, a counter-regulatory cytokine that overrides the anti-inflammatory activities of steroids. Cytokine Networks Inc....
Items per page:
1 - 9 of 9
BioCentury | Jan 8, 2015
Translation in Brief

Uptick for Lyme vaccine

Commercial interest in Lyme disease has all but ground to a halt since the withdrawal of the first vaccine, Lymerix, more than a decade ago, despite a tenfold increase in the U.S. incidence of the...
BioCentury | Jul 27, 1998
Company News

Cytokine other research news

...the potential for the agent to prevent toxicity from IL-2 and IL-12 in cancer treatment. Cytokine Networks Inc....
BioCentury | Jul 27, 1998
Company News

Cytokine other research news

...cells, the company said. Phase I testing of these cells as cancer therapy is ongoing. Cytokine Networks Inc....
BioCentury | Jul 27, 1998
Company News

Cytokine other research news

...the role of polyamine blockers in promoting the action of tumor necrosis factor against cancers. Cytokine Networks Inc....
BioCentury | Jun 8, 1998
Emerging Company Profile

Cytokine Networks Inc.

Cytokine Networks Inc. Seattle, Wash. Technology: Cytokine inhibitors, antivirals and vaccines to prevent disease Disease focus: Cancer, inflammatory diseases and HIV infection Clinical status: Phase I Founded: 1993 by the Picower Institute for Medical Research...
BioCentury | Jun 8, 1998
Emerging Company Profile

Cytokine Networks: Ready-made pipeline

...but not given a mandate to become an operating drug development company until December 1996, Cytokine Networks Inc....
BioCentury | Jun 1, 1998
Clinical News

CNI-1493 small molecule inhibitor of IL-2 toxicities: Cytokine Networks began U.S. Phase I testing

...CNI-1493 small molecule inhibitor of IL-2 toxicities Indication: Adjunct to IL-2 in cancer therapies Status: Cytokine Networks...
BioCentury | Apr 13, 1998
Clinical News

Autologous fibrocyte antigen-presenting cells: Cytokine Networks began Phase I testing

...Seattle, Wash. Product: Autologous fibrocyte antigen-presenting cells Indication: Treat sarcoma, melanoma and other cancers Status: Cytokine Networks...
BioCentury | Sep 15, 1997
Company News

Cytokine, Idec deal

...IDPH exclusively licensed therapeutic and diagnostic applications of Cytokine Networks' anti-macrophage inhibitory factor ( MIF ) antibody...
...MIF ) antibody technology. IDPH will make a $3 million preferred equity investment in Cytokine Networks...
...is designed to inhibit MIF, a counter-regulatory cytokine that overrides the anti-inflammatory activities of steroids. Cytokine Networks Inc....
Items per page:
1 - 9 of 9